Even the “Corriere Sociale,” the section of the Corriere della Sera dedicated to issues of volunteering and Third Sector, has published on February 27, 2015, an article on the commitment of CVBF and its activities in the field of rare diseases and paediatrics. The article emphasizes how the DEEP project significantly contributes to the paediatric research, by aiming to ensure to many children around the world the availability of a new formulation of deferiprone (DFP): the first oral iron chelator developed in Europe, specifically tested for them. In particular, DEEP will make deferiprone available as first-line treatment in children of any age, affected by β-thalassaemia major and other transfusion dependent haemoglobinopathies, the more frequent anaemia in the world (especially in the Mediterranean).
Related posts:
DEEP project – “Success story” for European Commission’s DG Research and Innovation
Drug safety of oral iron chelator deferiprone in children: a dissertation on the results of DEEP-3 Study
Rare diseases and Paediatrics – Article on the goals of CVBF as DEEP Coordinator
DEEP-3 study results published in the January issue of Haematologica